|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PELP1 |
Gene summary for PELP1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PELP1 | Gene ID | 27043 |
| Gene name | proline, glutamate and leucine rich protein 1 | |
| Gene Alias | MNAR | |
| Cytomap | 17p13.2 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | B4DEX7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 27043 | PELP1 | P49T-E | Human | Esophagus | ESCC | 4.98e-09 | 1.08e+00 | 0.1768 |
| 27043 | PELP1 | P52T-E | Human | Esophagus | ESCC | 2.56e-20 | 3.59e-01 | 0.1555 |
| 27043 | PELP1 | P54T-E | Human | Esophagus | ESCC | 4.73e-18 | 4.72e-01 | 0.0975 |
| 27043 | PELP1 | P56T-E | Human | Esophagus | ESCC | 5.48e-11 | 1.22e+00 | 0.1613 |
| 27043 | PELP1 | P57T-E | Human | Esophagus | ESCC | 2.69e-11 | 2.11e-01 | 0.0926 |
| 27043 | PELP1 | P61T-E | Human | Esophagus | ESCC | 7.35e-23 | 5.57e-01 | 0.099 |
| 27043 | PELP1 | P62T-E | Human | Esophagus | ESCC | 4.05e-27 | 5.78e-01 | 0.1302 |
| 27043 | PELP1 | P65T-E | Human | Esophagus | ESCC | 2.71e-19 | 3.37e-01 | 0.0978 |
| 27043 | PELP1 | P74T-E | Human | Esophagus | ESCC | 9.63e-23 | 7.49e-01 | 0.1479 |
| 27043 | PELP1 | P75T-E | Human | Esophagus | ESCC | 7.93e-21 | 5.11e-01 | 0.1125 |
| 27043 | PELP1 | P76T-E | Human | Esophagus | ESCC | 2.54e-19 | 4.27e-01 | 0.1207 |
| 27043 | PELP1 | P79T-E | Human | Esophagus | ESCC | 1.53e-25 | 4.67e-01 | 0.1154 |
| 27043 | PELP1 | P80T-E | Human | Esophagus | ESCC | 2.14e-26 | 7.38e-01 | 0.155 |
| 27043 | PELP1 | P82T-E | Human | Esophagus | ESCC | 2.74e-13 | 6.02e-01 | 0.1072 |
| 27043 | PELP1 | P83T-E | Human | Esophagus | ESCC | 5.02e-34 | 9.10e-01 | 0.1738 |
| 27043 | PELP1 | P84T-E | Human | Esophagus | ESCC | 2.95e-09 | 3.25e-01 | 0.0933 |
| 27043 | PELP1 | P89T-E | Human | Esophagus | ESCC | 2.31e-08 | 4.95e-01 | 0.1752 |
| 27043 | PELP1 | P91T-E | Human | Esophagus | ESCC | 1.22e-14 | 1.33e+00 | 0.1828 |
| 27043 | PELP1 | P104T-E | Human | Esophagus | ESCC | 4.09e-07 | 1.73e-01 | 0.0931 |
| 27043 | PELP1 | P107T-E | Human | Esophagus | ESCC | 9.12e-49 | 1.10e+00 | 0.171 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00436275 | Esophagus | ESCC | response to estrogen | 45/8552 | 75/18723 | 8.75e-03 | 3.08e-02 | 45 |
| GO:0043627 | Liver | Cirrhotic | response to estrogen | 30/4634 | 75/18723 | 2.52e-03 | 1.51e-02 | 30 |
| GO:00436271 | Liver | HCC | response to estrogen | 44/7958 | 75/18723 | 3.44e-03 | 1.55e-02 | 44 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PELP1 | SNV | Missense_Mutation | novel | c.834N>C | p.Leu278Phe | p.L278F | protein_coding | tolerated(0.71) | probably_damaging(0.923) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD | |
| PELP1 | SNV | Missense_Mutation | novel | c.787C>T | p.Leu263Phe | p.L263F | protein_coding | tolerated(0.18) | probably_damaging(0.986) | TCGA-A7-A6VX-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | CR | |
| PELP1 | SNV | Missense_Mutation | novel | c.3479N>G | p.Ala1160Gly | p.A1160G | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.994) | TCGA-AC-A8OQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PELP1 | SNV | Missense_Mutation | c.1961N>T | p.Ala654Val | p.A654V | protein_coding | tolerated(0.42) | possibly_damaging(0.743) | TCGA-B6-A0I9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
| PELP1 | SNV | Missense_Mutation | novel | c.1993N>C | p.Glu665Gln | p.E665Q | protein_coding | tolerated(0.26) | possibly_damaging(0.55) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| PELP1 | SNV | Missense_Mutation | rs774281042 | c.3091N>C | p.Thr1031Pro | p.T1031P | protein_coding | tolerated_low_confidence(0.18) | benign(0) | TCGA-BH-A1F5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| PELP1 | SNV | Missense_Mutation | c.2155N>T | p.Gly719Cys | p.G719C | protein_coding | tolerated(0.1) | possibly_damaging(0.658) | TCGA-C8-A12M-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| PELP1 | SNV | Missense_Mutation | c.1364T>C | p.Val455Ala | p.V455A | protein_coding | tolerated(0.13) | probably_damaging(0.941) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | ||
| PELP1 | insertion | In_Frame_Ins | novel | c.3496_3497insTCTGTTGCCCAGGCTGGAGTGCAGTGGCATGGTCTCAGCTCACTG | p.Pro1166delinsLeuCysCysProGlyTrpSerAlaValAlaTrpSerGlnLeuThrAla | p.P1166delinsLCCPGWSAVAWSQLTA | protein_coding | TCGA-A2-A0EM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |||
| PELP1 | insertion | Nonsense_Mutation | novel | c.1265_1266insGGCACAGCAGGAGGGGAGGTAGAAGAAG | p.Ile422MetfsTer8 | p.I422Mfs*8 | protein_coding | TCGA-AN-A041-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |